- Home
- DMRC vs APLT Comparison
DMRC vs APLT Comparison
Compare DMRC & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMRC
- APLT
- Stock Information
- Founded
- DMRC 2008
- APLT 2016
- Country
- DMRC United States
- APLT United States
- Employees
- DMRC N/A
- APLT N/A
- Industry
- DMRC EDP Services
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- DMRC Technology
- APLT Health Care
- Exchange
- DMRC Nasdaq
- APLT Nasdaq
- Market Cap
- DMRC 219.0M
- APLT 178.6M
- IPO Year
- DMRC N/A
- APLT 2019
- Fundamental
- Price
- DMRC $10.14
- APLT $1.38
- Analyst Decision
- DMRC Strong Buy
- APLT Buy
- Analyst Count
- DMRC 1
- APLT 5
- Target Price
- DMRC $30.00
- APLT $4.13
- AVG Volume (30 Days)
- DMRC 159.7K
- APLT 7.5M
- Earning Date
- DMRC 10-30-2025
- APLT 11-10-2025
- Dividend Yield
- DMRC N/A
- APLT N/A
- EPS Growth
- DMRC N/A
- APLT N/A
- EPS
- DMRC N/A
- APLT N/A
- Revenue
- DMRC $35,479,000.00
- APLT $121,000.00
- Revenue This Year
- DMRC N/A
- APLT N/A
- Revenue Next Year
- DMRC N/A
- APLT $5,935.35
- P/E Ratio
- DMRC N/A
- APLT N/A
- Revenue Growth
- DMRC N/A
- APLT N/A
- 52 Week Low
- DMRC $7.77
- APLT $0.30
- 52 Week High
- DMRC $48.32
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- DMRC 56.37
- APLT 67.08
- Support Level
- DMRC $9.19
- APLT $1.21
- Resistance Level
- DMRC $10.43
- APLT $1.50
- Average True Range (ATR)
- DMRC 0.60
- APLT 0.14
- MACD
- DMRC 0.15
- APLT 0.01
- Stochastic Oscillator
- DMRC 87.95
- APLT 81.65
About DMRC Digimarc Corporation
Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.